TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29485933

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise breaks (25% of heart rate reserve)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise breaks (50% of heart rate reserve)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-intensity exercise breaks (75% of heart rate reserve)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sedentary computer game breaks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall condition effect
Number of subjects: 39
Study: 29485988

Group type: EXPERIMENTAL
Intervention: ACCESS-care
Number of subjects: 115
Study: 29486396

Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day (sensitivity analysis)
Number of subjects: 150
Study: 29486663

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 112
Study: 29486723

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-1 immunotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemokine and immunosuppressive molecule expression profiles
Number of subjects: 0
Study: 29486737

Group type: EXPERIMENTAL
Intervention: Self-referrals
Number of subjects: 86

Group type: COMPARATOR
Intervention: Provider-referrals
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Overall syndemic health problems
Number of subjects: 86
Study: 29486784

Group type: EXPERIMENTAL
Intervention: Snacks (morning, afternoon, evening)
Number of subjects: 104265

Group type: COMPARATOR
Intervention: Main meals
Number of subjects: 104265
Study: 29486869

Group type: EXPERIMENTAL
Intervention: CORT (cortisol administration)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29486918

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Post-SIRT surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) followed by surgery
Number of subjects: 30
Study: 29486998

Group type: EXPERIMENTAL
Intervention: Late menopause
Number of subjects: 373

Group type: COMPARATOR
Intervention: Early menopause
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Delay in menopause by each year
Number of subjects: 373
Study: 29487023

Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiation therapy
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Baseline sexual aid utilization
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Sexual aids usage after radiation therapy
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: First-time use of sexual aids within 12 months
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: First-time use of sexual aids more than 12 months after radiation therapy
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Men who found sexual aids helpful at baseline
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Men who developed erectile dysfunction but found aids helpful
Number of subjects: 471
Study: 29487042

Group type: EXPERIMENTAL
Intervention: Neuro Vision Technology rehabilitation program
Number of subjects: 29
Study: 29487046

Group type: EXPERIMENTAL
Intervention: Sweetch app and digital body weight scale (DBWS)
Number of subjects: 55
Study: 29487070

Group type: EXPERIMENTAL
Intervention: Anti-CD22 moxetumomab pasudotox (50 µg/kg every other day for 3 doses in 4-week cycles)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Anti-CD22 moxetumomab pasudotox (50 µg/kg)
Number of subjects: 33
Study: 29487193

Group type: EXPERIMENTAL
Intervention: Pressure-sensing sheath (PSS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Radial arterial line (RAL)
Number of subjects: 40
Study: 29487219

Group type: EXPERIMENTAL
Intervention: Selinexor (65 mg/m, twice-a-week dosing)
Number of subjects: 14
Study: 29487221

Group type: EXPERIMENTAL
Intervention: Ablation therapy after six cycles of chemotherapy
Number of subjects: 8
Study: 29487556

Group type: EXPERIMENTAL
Intervention: Long-term pain treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29487566

Group type: EXPERIMENTAL
Intervention: GADA positive T2DM patients
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Low C-peptide levels in T2DM patients
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Gastroparesis Cardinal Symptom Index (GCSI)
Number of subjects: 203
Study: 29487697

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil- and irinotecan-based chemotherapy regimens (FOLFIRI or FOLFOXIRI) plus bevacizumab
Number of subjects: 0
Study: 29487870

Group type: EXPERIMENTAL
Intervention: Radon water therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no radon water therapy)
Number of subjects: 35
Study: 29488122

Group type: EXPERIMENTAL
Intervention: Capecitabine plus cisplatin (XP)
Number of subjects: 40
Study: 29488164

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 100
Study: 29488303

Group type: EXPERIMENTAL
Intervention: Glasdegib (100 mg) alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glasdegib (100 mg) following rifampin (600 mg) pre-treatment
Number of subjects: 12
Study: 29489073

Group type: EXPERIMENTAL
Intervention: Atomoxetine (pharmacotherapy for cannabis dependence)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MJQQ (Marijuana Quit Questionnaire)
Number of subjects: 23
Study: 29489427

Group type: EXPERIMENTAL
Intervention: Atezolizumab or nivolumab (anti-PD-1/PD-L1 antibodies)
Number of subjects: 60
Study: 29489559

Group type: EXPERIMENTAL
Intervention: Structured breast implants
Number of subjects: 502
Study: 29489633

Group type: EXPERIMENTAL
Intervention: Cryotherapy intervention for the prevention of venous ulcers
Number of subjects: 95
Study: 29489906

Group type: EXPERIMENTAL
Intervention: Authorized Generic (AG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison Generics (EG)
Number of subjects: 0
Study: 29490632

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICPIs)
Number of subjects: 4
Study: 29490648

Group type: EXPERIMENTAL
Intervention: Stage-based lifestyle modification intervention
Number of subjects: 50
Study: 29490682

Group type: EXPERIMENTAL
Intervention: 1 g of Tranexamic Acid (TXA)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: 0.5 g of Tranexamic Acid (TXA)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 29490680

Group type: EXPERIMENTAL
Intervention: BESMILE-HF program plus usual medications
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual medications
Number of subjects: 200
Study: 29490690

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 0.5 g
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 1 g
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: TA (0-2 g) in H patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Non-hemorrhagic (NH) group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Non-pregnant (NP) women
Number of subjects: 114
Study: 29490898

Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis initiated in a mobile stroke unit (MSU) with computed tomography (CT).
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional pathway with transport to hospital for CT and thrombolysis as per current procedure.
Number of subjects: 37
Study: 29490899

Group type: EXPERIMENTAL
Intervention: Samsung Galaxy S5
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Samsung Galaxy S6
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: LG G3
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 46
Study: 29490924

Group type: EXPERIMENTAL
Intervention: Presence of antiphospholipid antibodies (APAs)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Negative D-dimer results
Number of subjects: 307
Study: 29491412

Group type: EXPERIMENTAL
Intervention: BI 894999 (novel BET bromodomain inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of BI 894999 and CDK9 inhibitors
Number of subjects: 0
Study: 29491490

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 77
Study: 29493266

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 111
Study: 29493399

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Use of a walking aid
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: SwePASS total score ≤ 24
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: SwePASS total score 25-30
Number of subjects: 462
Study: 29493578

Group type: EXPERIMENTAL
Intervention: Cell-free DNA (cfDNA)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Maternal serum screening (MSS)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Maternal serum screening (MSS) in ART group
Number of subjects: 794

Group type: COMPARATOR
Intervention: Maternal serum screening (MSS) in spontaneous pregnancy (SP) group
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: cfDNA
Number of subjects: 794

Group type: COMPARATOR
Intervention: MSS
Number of subjects: 794
Study: 29493880

Group type: EXPERIMENTAL
Intervention: EXCEL 2 stent (n = 208)
Number of subjects: 419

Group type: COMPARATOR
Intervention: EXCEL stent (n = 211)
Number of subjects: 419
Study: 29494181

Group type: EXPERIMENTAL
Intervention: Repetition lag training for 9 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Active control program for 9 days
Number of subjects: 62
Study: 29494351

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic sacrocolpopexy
Number of subjects: 36
Study: 29494898

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Active rTMS responders
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham responders
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Non-responders
Number of subjects: 32
Study: 29496055

Group type: EXPERIMENTAL
Intervention: 3D-printed patient-specific surgical plates
Number of subjects: 10
Study: 29496125

Group type: EXPERIMENTAL
Intervention: Childhood-onset schizophrenia (COS) patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonpsychotic siblings of patients with COS
Number of subjects: 32
Study: 29496167

Group type: EXPERIMENTAL
Intervention: Piscroside C
Number of subjects: 0
Study: 29496473

Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Number of subjects: 20
Study: 29496499

Group type: EXPERIMENTAL
Intervention: Integrated proteomic classifier
Number of subjects: 685
Study: 29497297

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29497534

Group type: EXPERIMENTAL
Intervention: Intravenous IgM immunoglobulin therapy (IVIG group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29497535

Group type: EXPERIMENTAL
Intervention: High-dose norepinephrine (≥ 416 μg/kg/week)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Low-dose norepinephrine (not specified)
Number of subjects: 112
Study: 29497561

Group type: EXPERIMENTAL
Intervention: PROBE questionnaire
Number of subjects: 656
Study: 29497747

Group type: EXPERIMENTAL
Intervention: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Number of subjects: 8
Study: 29497956

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 42
Study: 29498038

Group type: EXPERIMENTAL
Intervention: Dupilumab (subcutaneous 300 mg weekly)
Number of subjects: 14
Study: 29498296

Group type: EXPERIMENTAL
Intervention: ASP2215 (gilteritinib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 0
Study: 29498742

Group type: EXPERIMENTAL
Intervention: ATV/r monotherapy (300/100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ATV/r triple therapy (300/100 mg + 2 NRTIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both ATV/r monotherapy and ATV/r triple therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATV/r monotherapy
Number of subjects: 0
Study: 29498923

Group type: EXPERIMENTAL
Intervention: IKZF1 deletions co-occurring with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion
Number of subjects: 991
Study: 29498925

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 113
Study: 29499622

Group type: EXPERIMENTAL
Intervention: Stress ulcer prophylaxis (SUP) using acid-suppression drugs
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for >48 hours
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: History of UGIB
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: Use of anticoagulants
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: SUP (acid-suppression drugs)
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: Hemostatic drugs
Number of subjects: 1416
Study: 29499645

Group type: EXPERIMENTAL
Intervention: Line-probe assays (LPA)
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: Pyrosequencing (PSQ)
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: MODS
Number of subjects: 1128

Group type: COMPARATOR
Intervention: MGIT
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: PSQ
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: LPA
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: PSQ and LPA
Number of subjects: 1128
Study: 29499662

Group type: EXPERIMENTAL
Intervention: Sorafenib at 800 mg/day
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 345
Study: 29499704

Group type: EXPERIMENTAL
Intervention: HIV status disclosure to male partners
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HIV status disclosure to family members
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Disclosure rates among newly-diagnosed women
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Disclosure rates among lost-to-follow-up women
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fear of divorce and intimate partner violence
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Assistance from healthcare workers
Number of subjects: 100
Study: 29499710

Group type: EXPERIMENTAL
Intervention: Progressive home-based resistance training using an elastic band in addition to usual care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 200
Study: 29499723

Group type: EXPERIMENTAL
Intervention: Increased counts of circulating CD14 monocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating counts of inflammatory monocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating counts of patrolling monocytes
Number of subjects: 0
Study: 29499740

Group type: EXPERIMENTAL
Intervention: Low-dose transdermal hydrogel MSCs (3 × 10)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29499753

Group type: EXPERIMENTAL
Intervention: OMPSQ-G (Orebro musculoskeletal pain screening questionnaire - German version)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: OMPSQ-G
Number of subjects: 50
Study: 29499766

Group type: EXPERIMENTAL
Intervention: High-volume (HV) HIIT group (40 min) with Mediterranean diet recommendations
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Low-volume (LV) HIIT group (20 min) with Mediterranean diet recommendations
Number of subjects: 177

Group type: COMPARATOR
Intervention: Attention control group with Mediterranean diet recommendations and physical activity without supervision
Number of subjects: 177
Study: 29499850

Group type: EXPERIMENTAL
Intervention: Higher plasma concentrations of s-adenosylmethionine (SAM)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Higher plasma concentrations of s-adenosylhomocysteine (SAH)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Higher plasma concentrations of homocysteine (Hcy)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: SAM:SAH ratio
Number of subjects: 118
Study: 29500138

Group type: COMPARATOR
Intervention: Acute cellular rejection (ACR)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Antibody-mediated rejection (AMR)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: ddcfDNA levels
Number of subjects: 157
Study: 29500154

Group type: EXPERIMENTAL
Intervention: Normalised whole-brain white matter fractional anisotropy (WWM-FA) measured by diffusion tensor imaging
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Normalised WWM-FA value lower than 0.91 in the validation cohort
Number of subjects: 185
Study: 29500157

Group type: EXPERIMENTAL
Intervention: Crush the Crave (CTC) app
Number of subjects: 1987
Study: 29500160

Group type: EXPERIMENTAL
Intervention: Testosterone injections and therapist-assisted progressive resistance training for 20 weeks
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Testosterone injections for 20 weeks without physical exercise
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Placebo injections for 20 weeks combined with 16 weeks of progressive strength training
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Testosterone injections for 20 weeks combined with 16 weeks of progressive strength training
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo injections without physical exercise for 20 weeks
Number of subjects: 192
Study: 29500161

Group type: EXPERIMENTAL
Intervention: Pharmacist-led, mHealth-based intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study: 29500162

Group type: EXPERIMENTAL
Intervention: Community Health Extension Workers (CHEWs) providing contraceptive subdermal implants
Number of subjects: 8125

Group type: COMPARATOR
Intervention: Nurses and midwives providing contraceptive subdermal implants
Number of subjects: 8125

Group type: EXPERIMENTAL
Intervention: CHEWs
Number of subjects: 8125

Group type: COMPARATOR
Intervention: Nurses and midwives
Number of subjects: 8125
Study: 29500202

Group type: EXPERIMENTAL
Intervention: Dental caries during pregnancy
Number of subjects: 4826

Group type: COMPARATOR
Intervention: Women without dental caries during pregnancy
Number of subjects: 4826
Study: 29500207

Group type: EXPERIMENTAL
Intervention: High socioeconomic status (SES) as measured by Winkler-Stolzenberg Index (WSI) or family income
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Higher physical activity
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 1206
Study: 29500572

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) 750 mg prophylaxis
Number of subjects: 207
Study: 29500837

Group type: EXPERIMENTAL
Intervention: Soft tissue grafting or implant surgery
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Sedation during surgery
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Pain pill use
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Nervousness prior to surgery
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Actual pain experienced
Number of subjects: 213
Study: 29501599

Group type: EXPERIMENTAL
Intervention: Deep healing (combination of transmural and mucosal healing)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Transmural healing with mucosal inflammation
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Mucosal and transmural inflammation
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 151
Study: 29501741

Group type: EXPERIMENTAL
Intervention: Community-wide, multi-level intervention including comic books, multi-generational nutrition and PA classes, teacher-led PA breaks, media literacy education, family nights, a farmer's market, and a community PA event (ciclovia) over 2 years.
Number of subjects: 900

Group type: COMPARATOR
Intervention: Two newsletters sent to the comparison community.
Number of subjects: 900
Study: 29501806

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1767
Study: 29502085

Group type: EXPERIMENTAL
Intervention: Coronary artery calcification (CAC) >0 AU in NSCP patients
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Cardiac events in NSCP patients
Number of subjects: 229

Group type: COMPARATOR
Intervention: Cardiac events in background population
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: CAC >100 AU in NSCP patients
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Frequency of cardiac endpoints
Number of subjects: 229
Study: 29502304

Group type: EXPERIMENTAL
Intervention: Accu-Chek (System A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: System C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: System D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin dosing errors (lay-users)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin dosing errors (study personnel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All SMBG systems
Number of subjects: 0
Study: 29502530

Group type: EXPERIMENTAL
Intervention: HIRREM® intervention
Number of subjects: 18
Study: 29502594

Group type: EXPERIMENTAL
Intervention: VABEM (vindesine, doxorubicin, carmustine, etoposide, and methylprednisolone)
Number of subjects: 51
Study: 29502924

Group type: EXPERIMENTAL
Intervention: Abbott FreeStyle Libre
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexcom G5 mobile
Number of subjects: 0
Study: 29503006

Group type: EXPERIMENTAL
Intervention: Percutaneous axillary artery access (pAxA) using two Perclose ProGlide devices
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Follow-up of patients who underwent pAxA
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Anatomic characteristics of the AxA
Number of subjects: 34
Study: 29504053

Group type: EXPERIMENTAL
Intervention: Duodenal-Jejunal Bypass Liner (DJBL)
Number of subjects: 77
Study: 29504262

Group type: EXPERIMENTAL
Intervention: High Fat/High Sugar (HF/HSS) intake
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Energy Density (EnDen)
Number of subjects: 214